Application-level market taxonomy reveals how reimbursement codes and procedural volumes shape demand. Orthopaedic and trauma surgery consumed 38 % of 2023 unit shipments, propelled by high revision rates and the need for real-time implant positioning that DRF’s low-dose pulse mode delivers. Cardiovascular applications, constrained by hybrid OR capital budgets yet reimbursed at premium codes, represented 26 % of revenue despite lower unit volume, reflecting detector spectral purity requirements. Gastroenterology and urology endoscopic suites favour compact mobile DRF for cholangiography and nephrolithotomy, contributing 18 % of sales where space-sharing across specialties amortizes equipment cost. _Neurology and interventional pain** clinics, constrained by outpatient payment caps, purchase refurbished fixed systems, yielding 12 % share but fastest volume CAGR as office-based labs proliferate. Remaining share covers veterinary and R&D uses, where price elasticity tests component cost floors.